BUY Karur Vysya Bank

Growth moderates, but delivers superior RoA

BFSI - Banks > Result Update > May 16, 2023

Karur Vysya Bank (KVB) posted a strong PAT beat yet again, of 15% at Rs3.4bn (Emkay: Rs2.9bn), boosted by robust & stable margins at 4.4%, higher recovery from written-off accounts, albeit partly offset by higher provisions, incl. restructured loans. Asset quality continues to improve, with NNPA now down to 0.7% from 2.3% a year ago. But gross credit growth was a tad disappointing, at 13% YoY/3% QoQ, and may stay moderate at 14% YoY in FY24E.

Despite tempering our growth estimates and raising our operational cost forecast, we revise FY24E earnings by 7%, building-in the lower LLP. We expect KVB to deliver a healthy RoA/RoE of 1.5-1.4%/15% over FY24-26E. Bank remains our top pick in the small-cap banking space, given its superior return ratios, sturdy capital ratios and Mgmt credibility. We retain BUY with TP of Rs155/sh, valuing the bank at 1.1x Mar-25E ABV (vs 1.2x Dec-24E ABV earlier).

Karur Vysya Bank: Financial Snapshot (Standalone)										
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E					
Net profit	6,733	11,061	14,115	15,986	17,800					
Loan growth (%)	8.5	15.5	14.4	15.2	16.0					
NII growth (%)	15.1	23.3	9.8	11.2	12.6					
NIM (%)	3.7	4.1	4.0	3.9	3.8					
PPOP growth (%)	26.2	51.9	6.4	10.1	15.3					
Adj. EPS (Rs)	8.4	13.8	17.6	19.9	22.2					
Adj. EPS growth (%)	87.2	63.9	27.6	13.3	11.3					
Adj. BV (INR)	83.2	102.7	118.7	135.7	154.4					
Adj. BVPS growth (%)	17.2	23.5	15.6	14.4	13.8					
RoA (%)	0.9	1.3	1.5	1.4	1.4					
RoE (%)	9.3	13.7	15.4	15.3	14.9					
P/E (x)	11.6	7.1	5.5	4.9	4.4					
P/ABV (x)	1.2	0.9	0.8	0.7	0.6					
	1.2	0.5	0.0	0.7	0.0					

Source: Company, Emkay Research

Growth moderates, but strong margins sustain

Overall gross credit growth was moderate at 13% YoY/3% QoQ (net 16% YoY/2% QoQ), mainly due to de-growth in the corporate book, while growth in agri, SME and retail remained healthy. Retail growth was mainly driven by mortgage/LAP and Gold loan; that said, the bank now targets ramping up its MFI business, for which it has entered into tie ups with BCs (business correspondents). Bank would look to grow its RAM book and, thereby, achieve better margins. Despite increasing cost pressures, KVB delivered strong & stable NIMs at 4.4%, benefiting from the continued asset-book repricing. Bank believes that funding cost will inch up in FY24, which will be partly offset by MCLR book (47%) repricing (25% pending).

NNPA improve below 1% led by lower slippages/higher write-offs

Fresh slippages were in line with our expectations, at Rs2.2bn/1.6% of loans, while slippages in the Corporate/SME verticals were higher. However, better recoveries and accelerated write-offs led to a 39bps QoQ reduction in the GNPA ratio to 2.3% and to NNPA at 0.75%. The restructured book too contracted, to Rs9.8bn/1.5% of loans, from 1.9% in Q3 on which it carries 21% PCR. Bank expects gross slippages of ~1% and net slippages to be negative in FY24 as well; this should lead to further improvement in GNPA ratio. Bank expects LLP to be 0.75%, but we conservatively build-in a higher LLP, at 1%, factoring-in some build-up towards PCR being lower than 70% as well as weakening macro-conditions.

Outlook and Valuations

KVB remains our top pick in the small-cap banking space, given its superior return ratios (RoA/RoE of 1.5-1.4%/15% over FY24-26E), healthy capital ratios and Management credibility. We retain BUY, with TP of Rs155/share, valuing the bank at 1.1x Mar-25E ABV (vs 1.2x Dec-24E ABV earlier). **Key risks:** Slower-than-expected growth, faster decline in CASA leading to cost pressure, and resurgence of NPAs in the retail/SME sector due to macro dislocation.



Ticker

TARGET PRICE (Rs): 155

Target Price – 12M	Mar-24
Change in TP (%)	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	59.1
CMP (15-May-23) (Rs)	97.4

Stock Data

Stock Bata	Herei
52-week High (Rs)	116
52-week Low (Rs)	42
Shares outstanding (mn)	799.2
Market-cap (Rs bn)	78
Market-cap (USD mn)	946
Net-debt, FY24E (Rs mn)	3,716
ADTV-3M (mn shares)	2
ADTV-3M (Rs mn)	224.5
ADTV-3M (USD mn)	2.7
Free float (%)	97.0
Nifty-50	18,399
INR/USD	82.3
Shareholding, Mar-23	
Promoters (%)	2.2
FPIs/MFs (%)	17.9/30.8

Price Performance									
(%)	1M	3M	12M						
Absolute	(2.3)	(6.7)	130.5						
Rel. to Nifty	(5.3)	(8.7)	97.7						



Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480

Heet Khimawat

heet.khimawat@emkayglobal.com +91 22 6612 1275


Dixit Sankharva

dixit.sankharva@emkayglobal.com +91 22 6612 1281

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>Please refer to Refer to Important Disclosures at the end of the last page of the report on Restrictions on Distribution In Singapore, this research report or research 5/ this report 7.58 PM analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


Story in Charts

Exhibit 1: Overall gross credit growth slipped to 13% due to decline in the corporate book




Source: Company, Emkay Research

Exhibit 3: CASA ratio moderated due to de-growth in the CA book




Source: Company, Emkay Research

Exhibit 5: Negative net slippages + higher write-offs led to NNPA falling below 1%



Source: Company, Emkay Research


Exhibit 7: We expect steady growth in return ratios, led by better growth and lower LLP



Source: Company, Emkay Research


Exhibit 2: Bank has a relatively well balanced portfolio

Portfolio Breakup (%)




Source: Company, Emkay Research





Source: Company, Emkay Research

Exhibit 6: Corporate and Commercial stress is now behind, leading to improvement in segmental NPAs



Source: Company, Emkay Research

Exhibit 8: The stock currently trades at 0.8x one-year forward ABV



Source: Bloomberg, Emkay Research

rch is intended This report is intended for team emkay @ whitemarguesolutions com use and downloaded at 05/16/2023 07:58 PM. Emkay Résearch is also available on www.emkaygloal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 9: Actuals vs. Estimates (Q4FY23)

(Rs mn)			Var	iation	Comments	
(K3 IIII)	Actuals	Emkay	Consensus	Emkay	Consensus	
Net income	12,934	11,411	11,762	13%	10%	Better margins and higher other income led to a beat
РРОР	7,391	5,939	5,548	24%	33%	Higher Net income and in-line opex led to a beat
PAT	3,378	2,927	2,802	15%	21%	Higher PPOP, partly offset by higher LLP, led to a beat

Source: Company, Emkay Research

Exhibit 10: Quarterly Summary

(Rs mn)	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	YoY (%)	QoQ (%)	FY23A	FY24E	YoY (%)
Interest Earned	14,093	14,735	15,795	16,952	17,683	25	4	65,166	78,541	21
Interest Exp	6,993	7,277	7,581	8,062	8,757	25	9	31,677	41,767	32
Net Interest Income	7,099	7,459	8,214	8,890	8,926	26	0	33,488	36,775	10
Global NIMs (reported)	3.82	3.85	4.10	4.36	4.37	55bps	1bps	4.14	3.99	-16bps
Non-interest Income	2,055	1,991	2,416	3,175	4,008	95	26	11,589	13,097	13
Operating Expenses	4,741	4,695	4,906	5,175	5,543	17	7	20,320	23,539	16
Pre Provisioning Profit	4,413	4,755	5,723	6,890	7,391	67	7	24,758	26,334	6
Provision & Contingencies	1,401	1,546	2,272	3,641	2,930	109	-20	10,389	7,470	-28
РВТ	3,012	3,208	3,451	3,249	4,460	48	37	14,369	18,863	31
Income Tax Expense (Gain)	877	921	949	356	1,082	23	204	3,308	4,748	44
Net Profit/(Loss)	2,135	2,288	2,502	2,893	3,378	58	17	11,061	14,115	28
Gross NPA (%)	5.96	5.21	3.97	2.66	2.27	-369bps	-39bps	2.27	1.69	-58bps
Net NPA (%)	2.28	1.91	1.36	0.89	0.74	-154bps	-15bps	0.74	0.51	-23bps
Deposits (Rs bn)	685	712	736	762	766	12	1	766	869	13
Net Advances (Rs bn)	547	576	602	617	631	16	2	631	722	14

Source: Company, Emkay Research

Exhibit 11: Revision in Estimates

Y/E Mar (Rs mn)		FY24E			FY25E		FY26E
	Earlier	Revised	Change	Earlier	Revised	Change	Introduced
Net income	50,021	49,872	-0.3%	58,665	55,634	-5.2%	63,343
PPOP	27,175	26,334	-3.1%	32,529	28,994	-10.9%	33,420
PAT	13,240	14,115	6.6%	16,337	15,986	-2.1%	17,800
EPS (Rs)	16.5	17.6	6.6%	20.4	19.9	-2.1%	22.2
BV (Rs)	120.2	122.1	1.6%	137.6	139.3	1.2%	158.5

Source: Company, Emkay Research

Exhibit 12: Key Assumptions	5			
	FY23A	FY24E	FY25E	FY26E
Loan Growth (%)	15.5	14.4	15.2	16.0
Deposit Growth (%)	11.9	13.3	14.7	16.0
NIM (%)	4.1	4.0	3.9	3.8
GNPA (%)	2.3	1.7	1.5	1.5
Credit Cost (%)	1.5	1.0	1.0	1.1

Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 05/16/2023.07:58 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 13: Quarterly Summary

Exhibit 15. Quarterly Summary	,								
	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Loans (Rs mn)	503,635	499,620	513,813	532,270	546,612	575,590	601,614	617,090	631,341
Growth YoY (%)	9.3	8.3	7.4	7.5	8.5	15.2	17.1	15.9	15.5
Growth QoQ (%)	1.7	(0.8)	2.8	3.6	2.7	5.3	4.5	2.6	2.3
Liability Profile & Margins									
Deposits (Rs mn)	632,784	643,980	654,101	668,710	684,860	711,680	736,141	761,750	766,376
Growth YoY (%)	7.1	7.2	7.0	7.7	8.2	10.5	12.5	13.9	11.9
Growth QoQ (%)	1.9	1.8	1.6	2.2	2.4	3.9	3.4	3.5	0.6
CASA (%)	34.2	35.0	35.4	36.1	34.9	36.4	35.2	33.9	33.2
CA (%)	10.2	10.0	10.7	11.1	10.1	11.2	10.9	10.3	9.7
SA (%)	24.0	25.0	24.8	25.0	24.8	25.2	24.3	23.5	23.5
Branches (No. of)	780	781	781	781	789	789	792	792	799
NIM (%)	3.46	3.55	3.74	3.68	3.82	3.85	4.10	4.36	4.37
Asset Quality (%)									
GNPA	7.9	8.0	7.4	7.0	6.0	5.2	4.0	2.7	2.3
NNPA	3.4	3.7	3.0	2.6	2.3	1.9	1.4	0.9	0.7
PCR	58.5	55.7	61.3	65.1	63.3	64.7	66.7	67.1	67.9
Capital Adequacy (%)									
CRAR	19.0	19.1	18.8	18.8	19.5	19.2	18.3	17.9	18.6
Tier I	17.0	17.0	16.8	16.8	17.5	17.3	16.4	16.0	16.8
ROE decomposition (%)									
NII	3.3	3.4	3.6	3.6	3.6	3.6	3.9	4.1	4.0
Other Income	1.2	1.1	0.9	1.0	1.0	1.0	1.1	1.4	1.8
Opex	3.1	2.3	2.5	2.5	2.4	2.3	2.3	2.4	2.5
PPOP	1.4	2.2	2.0	2.1	2.2	2.3	2.7	3.1	3.3
Provisioning Cost	0.4	1.3	0.9	0.8	0.7	0.8	1.1	1.7	1.3
PBT	1.0	0.9	1.1	1.3	1.5	1.6	1.6	1.5	2.0
ROA	0.6	0.6	0.9	1.0	1.1	1.1	1.2	1.3	1.5
ROE	6.0	6.2	9.3	10.2	11.4	11.9	12.7	14.3	16.1

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 05/16/2023 07:58 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Karur Vysya Bank : Standalone Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Interest Income	55,877	65,166	78,541	87,147	97,619
Interest Expense	28,723	31,677	41,767	46,264	51,591
Net interest income	27,154	33,488	36,775	40,882	46,028
NII growth (%)	15.1	23.3	9.8	11.2	12.6
Other income	7,691	11,589	13,097	14,752	17,315
Total Income	34,844	45,078	49,872	55,634	63,343
Operating expenses	18,542	20,320	23,539	26,640	29,923
РРОР	16,302	24,758	26,334	28,994	33,420
PPOP growth (%)	26.2	51.9	6.4	10.1	15.3
Core PPOP	16,804	25,009	25,334	27,494	31,170
Provisions & contingencies	6,993	10,389	7,470	7,630	9,632
PBT	9,309	14,369	18,863	21,363	23,788
Extraordinary items	0	0	0	0	0
Tax expense	2,577	3,308	4,748	5,377	5,987
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	6,733	11,061	14,115	15,986	17,800
PAT growth (%)	87.3	64.3	27.6	13.3	11.3
Adjusted PAT	6,733	11,061	14,115	15,986	17,800
Diluted EPS (Rs)	8.4	0.0	0.0	0.0	0.0
Diluted EPS growth (%)	86.9	(100.0)	0.0	0.0	0.0
DPS (Rs)	1.6	2.0	2.5	2.8	3.0
Dividend payout (%)	19.0	14.5	14.2	14.0	13.5
Effective tax rate (%)	27.7	23.0	25.2	25.2	25.2
Net interest margins (%)	3.7	4.1	4.0	3.9	3.8
Cost-income ratio (%)	53.2	45.1	47.2	47.9	47.2
Shares outstanding (mn)	800.0	802.1	802.1	802.1	802.1

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	1,600	1,604	1,604	1,604	1,604
Reserves & surplus	74,362	84,236	96,347	110,087	125,482
Net worth	75,962	85,841	97,951	111,691	127,086
Deposits	684,860	766,376	868,608	996,439	1,156,309
Borrowings	13,391	14,320	16,683	19,636	23,327
Interest bearing liab.	698,250	780,696	885,290	1,016,075	1,179,636
Other liabilities & prov.	26,500	35,258	48,882	55,860	56,740
Total liabilities & equity	800,713	901,794	1,032,123	1,183,626	1,363,462
Net advances	546,612	631,341	722,343	831,866	965,093
Investments	172,161	188,083	212,095	242,391	275,041
Cash, other balances	49,262	46,951	53,117	55,884	58,982
Interest earning assets	768,034	866,376	987,556	1,130,141	1,299,115
Fixed assets	4,785	4,350	6,992	7,804	8,712
Other assets	27,894	31,068	37,576	45,681	55,635
Total assets	800,713	901,794	1,032,123	1,183,626	1,363,462
BVPS (Rs)	95.0	107.0	122.1	139.3	158.5
Adj. BVPS (INR)	83.2	102.7	118.7	135.7	154.4
Gross advances	568,315	641,241	731,014	840,667	975,173
Credit to deposit (%)	79.8	82.4	83.2	83.5	83.5
CASA ratio (%)	34.9	33.2	32.2	32.1	32.1
Cost of deposits (%)	4.2	4.2	5.0	4.8	4.7
Loans-to-Assets (%)	68.3	70.0	70.0	70.3	70.8
Net advances growth (%)	8.5	15.5	14.4	15.2	16.0
Deposit growth (%)	8.2	11.9	13.3	14.7	16.0
Book value growth (%)	9.0	12.7	14.1	14.0	13.8

Source: Company, Emkay Research

Source: Company, Emkay Research

Asset quality and other metrics										
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E					
Asset quality										
Gross NPLs	34,311	14,581	12,388	12,572	14,401					
Net NPLs	12,608	4,681	3,716	3,772	4,320					
GNPA ratio (%)	6.0	2.3	1.7	1.5	1.5					
NNPA ratio (%)	2.3	0.7	0.5	0.5	0.4					
Provision coverage (%)	63.3	67.9	70.0	70.0	70.0					
Gross slippages	8,427	6,540	7,310	9,247	12,190					
Gross slippage ratio (%)	1.6	1.2	1.0	1.1	1.3					
LLP ratio (%)	1.3	1.5	1.0	1.0	1.1					
NNPA to networth (%)	16.2	5.3	3.7	3.3	3.3					
Capital adequacy										
Total CAR (%)	19.5	18.6	18.5	18.3	18.0					
Tier-1 (%)	17.5	16.8	17.0	16.9	16.8					
CET-1 (%)	17.5	16.9	17.0	17.0	16.8					
RWA-to-Total Assets (%)	52.0	54.4	54.0	54.0	54.0					
Miscellaneous										
Total income growth (%)	(0.5)	20.7	19.4	11.2	12.8					
Opex growth (%)	(6.7)	9.6	15.8	13.2	12.3					
Core PPOP growth (%)	56.4	48.8	1.3	8.5	13.4					
PPOP margin (%)	25.6	32.3	28.7	28.5	29.1					
PAT/PPOP (%)	41.3	44.7	53.6	55.1	53.3					
LLP-to-Core PPOP (%)	43.1	33.8	23.6	25.9	29.9					
Yield on advances (%)	8.9	9.2	9.7	9.3	9.0					
Cost of funds (%)	4.2	4.3	5.0	4.9	4.7					

Source: Company, Emkay Research

Valuations and key Ratios Y/E Mar FY22 FY23 FY24E FY25E FY26E P/E (x) 11.6 7.1 5.5 4.9 4.4 P/B (x) 0.9 0.8 0.7 0.6 1.2 P/ABV (x) 1.2 0.9 0.8 0.7 0.6 P/PPOP (x) 4.8 3.2 3.0 2.7 2.3 Dividend vield (%) 2.1 2.6 3.1 1.6 2.9 DuPont-RoE split (%) NII/avg assets 3.5 3.9 3.8 3.7 3.6 Other income 1.0 1.4 1.4 1.3 1.4 0.9 0.9 Fee income 0.8 0.9 0.9 Opex 2.4 2.4 2.4 2.4 2.3 PPOP 2.1 2.9 2.7 2.6 2.6 Core PPOP 2.9 2.6 2.4 2.2 2.5 Provisions 0.9 1.2 0.8 0.7 0.8 Tax expense 0.3 0.4 0.5 0.5 0.5 1.3 RoA (%) 0.9 1.5 1.4 1.4 10.6 10.5 10.5 10.6 10.7 Leverage ratio (x) RoE (%) 9.3 13.7 15.4 15.3 14.9 Quarterly data Rs mn, Y/E Mar 04FY22 01FY23 **02FY23 O3FY23** 04FY23 NII 7,099 7,459 8,214 8,890 8,926 NIM (%) 3.8 3.9 4.1 4.4 4.4 PPOP 4,413 4.755 5.723 6,890 7,391 PAT 2,135 2,288 2,502 2,893 3,378 EPS (Rs) 2.67 2.86 3.13 3.62 4.21

Source: Company, Emkay Research

This report is intended for team emkay@wbitemarguesolutions com use and downloaded at 05/16/2023 07:58 PM Emkay Résearch is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	CMP (INR)	TP (INR)	Rating	Analyst
09-Mar-23	104	155	Buy	Anand Dama
23-Jan-23	109	155	Buy	Anand Dama
22-Oct-22	91	125	Buy	Anand Dama
03-Oct-22	79	95	Buy	Anand Dama
30-Aug-22	69	95	Buy	Anand Dama
26-Jul-22	59	78	Buy	Anand Dama
22-May-22	45	72	Buy	Anand Dama
01-Feb-22	51	72	Buy	Anand Dama
11-Nov-21	58	72	Buy	Anand Dama
05-Aug-21	47	62	Buy	Anand Dama
01-Jun-21	56	62	Hold	Anand Dama
12-Feb-21	55	62	Hold	Anand Dama
20-Jan-21	46	53	Hold	Anand Dama
03-Nov-20	32	33	Hold	Anand Dama
01-Aug-20	35	29	Sell	Anand Dama
26-Jun-20	37	29	Sell	Anand Dama

RECOMMENDATION HISTORY - TREND



Source: Bloomberg, Company, Emkay Research

Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 05/16/2023.07:58 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India, EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkavglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkavglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 05/16/2023 07:58 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for gualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1 the securities recommended in this report as of May 16, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report 3. during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of May 16, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject 5 company at the end of the month immediately preceding the May 16, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- 7 EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.	
BUY	Over 15%	
HOLD	Between -5% to 15%	
SELL	Below -5%	

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 05/16/2023 07:58 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.